TX-VINCENT-LOUIS-MOGAS
MOGAS mourns the death of their beloved chairman and founder Vincent Louis Mogas, who died on May 2, 2024 in Houston, Texas. Louis spent his life building a valve manufacturing business and a company culture that stood for goodness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240503919754/en/
V. Louis Mogas, Founder and Chairman of MOGAS Industries (1939 - 2024) (Photo: MOGAS Industries Inc.)
MOGAS Industries was formed in May 1973 when Louis Mogas purchased a small machine shop in Houston. He soon acquired the rights to service and manufacture ball valves from Cameron Iron Works. Under Louis' leadership, the Company studied valve failures and established an R&D department that customized valves for specific applications. Since 2000, MOGAS has established sales and service offices in Australia, China, Europe, Canada, South America, Middle East and India.
Early on, Louis Mogas introduced business behaviors that became the foundation of the Company's core values--everyone is the CEO of something, make work fun, do what's right--to name a few. His belief that work can be fun and honorable, and that there is one team at MOGAS drive the Company's business principles today.
While Louis received many Company awards, including The Inc. 500 Fastest Growing Private Companies, multiple Best Companies to Work For in Texas, vendor excellence, Texas Family Large Business of the Year Finalist, and Best Quality Product, he was most proud of his and his family's philanthropy, and of employee fund raising and volunteerism contributions. These include Ronald McDonald House Houston, The Periwinkle Foundation, Camp for All, National Multiple Sclerosis Association, and several Houston district schools. In 2017 Louis Mogas was honored as a distinguished alumni at Texas A&M University, Kingsville for the creation of the Mogas Family Perseverance Scholarship Endowment. MOGAS Industries also awards scholarships and educational grants to employees and their children, and mentors summer hire interns.
The family of Louis Mogas, the MOGAS Executive Leadership Team and our employees worldwide are mourning the loss of a tremendous man whose leadership was only matched by his passion and fervor for life and serving others. We all carry the lessons that Louis shared with us in our hearts and we will continue to share his legacy to the world through our work and in our lives.
"Always live out your values in your work, so that when you drive home at the end of each day, you can feel proud of yourself." Louis Mogas
ABOUT MOGAS INDUSTRIES, INC.
MOGAS Industries is the most trusted severe service technology company offering severe service valves, surface engineering/coating, modular process units, and aftermarket support. Our world-renowned, application-specific products and service are best-in-class for critical applications in power, mining, oil & gas, refining, chemical/petrochemical, pulp & paper and specialty industries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503919754/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom